Conteduca Vincenza, Mosca Alessandra, Brighi Nicole, de Giorgi Ugo, Rescigno Pasquale
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy.
Cells. 2021 Jan 19;10(1):193. doi: 10.3390/cells10010193.
Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical treatments inevitably develop metastatic disease. Patient stratification is therefore key in this type of cancer, and there is an urgent need for prognostic biomarkers that can define patients' risk of cancer-related death. In the last 10 years, multiple prognostic factors have been identified and studied. Here, we review the literature available and discuss the most common aberrant genomic pathways in metastatic castration-resistant prostate cancer shown to have a prognostic relevance in this setting.
前列腺癌是男性中最常见的癌症之一，也是癌症相关死亡的常见原因。尽管在这种肿瘤的诊断和治疗方面取得了重大进展，但接受根治性治疗后复发的患者不可避免地会发展为转移性疾病。因此，患者分层是这类癌症的关键，迫切需要能够确定患者癌症相关死亡风险的预后生物标志物。在过去10年中，已经确定并研究了多种预后因素。在此，我们回顾现有文献，并讨论在转移性去势抵抗性前列腺癌中显示与这种情况具有预后相关性的最常见异常基因组途径。
